Already a member? Click here to login.
Already a member? Click here to login.
Sanofi is pleased to advise health care professionals that, as of 1 December 2016, TOUJEO® (300 units/mL) will be available in Australia as a private prescription for the treatment of diabetes mellitus in adults.
Toujeo® SoloStar® is a prefilled pen that contains a longer-acting1 formulation of insulin glargine (300 units/mL) compared with Lantus® (insulin glargine 100 units/mL). Toujeo is designed for once-daily subcutaneous administration.
Toujeo is not currently available on the Pharmaceutical Benefits Scheme (PBS) and will not be available at a PBS-subsidised price, so patients will incur out of pocket costs. As an indication, Sanofi’s price to wholesalers for a pack of 5 pens will be $119.05 (incl. GST). Patients should allow for wholesaler and pharmacy fees which may vary from pharmacy to pharmacy. We recommend advising patients to check with their pharmacist to determine the cost of having their Toujeo prescription dispensed.
Toujeo (300 units/mL) will appear in commonly used script writing software.
It is important to note that this strength of insulin glargine (300 units/mL [Toujeo]) is not bioequivalent and therefore not automatically interchangeable to other basal insulins and will require dose adjustment.
Some guidance material on how to initiate a patient on Toujeo is attached with this correspondence. An educational leaflet for patients is also attached for distribution to patients treated with Toujeo.
Please review the Product Information before prescribing.
For more information, please download and view letter from Sanofi.
Sanofi is pleased to advise health care professionals that, as of 1 December 2016, TOUJEO® (300 units/mL) will be available in Australia as a private prescription for the treatment of diabetes mellitus in adults.
Toujeo® SoloStar® is a prefilled pen that contains a longer-acting1 formulation of insulin glargine (300 units/mL) compared with Lantus® (insulin glargine 100 units/mL). Toujeo is designed for once-daily subcutaneous administration.
Toujeo is not currently available on the Pharmaceutical Benefits Scheme (PBS) and will not be available at a PBS-subsidised price, so patients will incur out of pocket costs. As an indication, Sanofi’s price to wholesalers for a pack of 5 pens will be $119.05 (incl. GST). Patients should allow for wholesaler and pharmacy fees which may vary from pharmacy to pharmacy. We recommend advising patients to check with their pharmacist to determine the cost of having their Toujeo prescription dispensed.
Toujeo (300 units/mL) will appear in commonly used script writing software.
It is important to note that this strength of insulin glargine (300 units/mL [Toujeo]) is not bioequivalent and therefore not automatically interchangeable to other basal insulins and will require dose adjustment.
Some guidance material on how to initiate a patient on Toujeo is attached with this correspondence. An educational leaflet for patients is also attached for distribution to patients treated with Toujeo.
Please review the Product Information before prescribing.
For more information, please download and view letter from Sanofi.
